Iria Fernández

169P Early-onset gastrointestinal cancer (EOGIC) in Spain: Preliminary analysis of the prospective TEOGIC study

I. Labiano, Ana Elsa Huerta, Alba Lecumberri, Irene Caseda et autres

es (code pays fourni par la source)

Dual triggering for final oocyte maturation. A narrative review

Adriana Riobó, A Acosta, Lorena Martinez-Rocca, Esther Taboas et autres

fertilization (IVF). When both drugs are used sequentially, it is called "double trigger", but this strategy is rarely used clinically. This review explores the rationale for using dual triggering and compares its reproductive outcome with conventional hCG triggering. Variability in protocols, inclusion …

es, co (code pays fourni par la source)

Risk of preeclampsia and other pregnancy complications in frozen single euploid embryo transfers after natural versus artificial endometrial preparation: A truncated randomized controlled trial

José Bellver, António Pellicer, Laura Caracena, Vicente Serra et autres

es, co (code pays fourni par la source)

Reproductive Outcomes of Oocyte Donation in Patients With Uterine Mullerian Anomalies

Elkin Muñoz, Iria Fernández, Nuria Pellicer, Giulia Mariani et autres

(Abstracted from Fertil Steril 2023;120(4):850–859) Uterine müllerian anomalies (UMAs) are anatomic malformations of the female genital tract found in 5.5% of the general population but 24.5% of women with a history of miscarriage and infertility. Studies identifying the relationships between UMAs and …

co, es (code pays fourni par la source)

REPRODUCTIVE OUTCOMES OF FEMALES CARRYING A FMR1 MUTATED GENE

Jesús Arroyo Fernández de Aguilar, Iria Fernández, Esther Taboas, Nicolás Garrido Puchalt et autres

es (code pays fourni par la source)

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

Jean‐Emmanuel Kurtz, Éric Pujade-Lauraine, Ana Oaknin, Lisa Belin et autres

PURPOSE Platinum-based doublets with concurrent and maintenance bevacizumab are standard therapy for ovarian cancer (OC) relapsing after a platinum-free interval (PFI) >6 months. Immunotherapy may be synergistic with bevacizumab and chemotherapy. PATIENTS AND METHODS ATALANTE/ENGOT-ov29 (ClinicalTrials.gov identifier: NCT02891824 ), a placebo-controlled double-blinded …

fr, es, at, cz, be, il, de (code pays fourni par la source)

Reproductive outcomes of oocyte donation in patients with uterine Müllerian anomalies

Elkin Muñoz, Iria Fernández, Nuria Pellicer, Giulia Mariani et autres

co, es (code pays fourni par la source)

Oocyte donation outcome after oncological treatment in cancer survivors

Elkin Muñoz, Iria Fernández, María del Mar Fernández Martínez, Antonia Tocino et autres

es (code pays fourni par la source)

Treatment of Luteal Phase Defects in Assisted Reproduction

Elkin Muñoz, Esther Taboas, Susana Portela, Jesús Arroyo Fernández de Aguilar et autres

Abnormal luteal function is a common issue in assisted reproduction techniques associated with ovarian stimulation probably due to low levels of LH in the middle and in the late luteal phase. This defect seems to be associated with supraphysiological steroid levels at …

es (code pays fourni par la source)

Conformed radiotherapy and chemotherapy with cisplatin/tegafur in cervix cancer

M. Caeiro, Gerardo Huidobro, Herencia-Lagunar Elena, Patricia Willisch et autres

es (code pays fourni par la source)

The Role of LH in Ovarian Stimulation

Elkin Muñoz, Ernesto Bosch, Iria Fernández, Susana Portela et autres

LH is a glycoprotein that plays a crucial role in folliculogenesis during the natural ovarian cycles. It has the same activity and shares receptors with hCG. However the use of LH in combination with FSH in controlled ovarian stimulation remains controversial. A …

es (code pays fourni par la source)

Neoadjuvant chemoradiotherapy in rectal cancer patients (pt) with oxaliplatin (Ox) and capecitabine (Cp): Results of a phase II trial

J. Gasent Blesa, Vicente Alberola Candel, Óscar Juan, Víctor Marco et autres

e15101 Background: Between April 2006 and May 2008, 27 rectal adenocarcinoma pt were included (cT3: 25 pt, T4: 2 pt, N0: 11 Pt, N+: 16 pt), stages II-III, RMN staged, 14 male and 13 female. Mehtod: Neoadjuvant treatment was: Ox: 50 mg/m2 …

es (code pays fourni par la source)